Hepatology International-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=944315, encodeId=e47f944315e8, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：经过1个月大修，三个审稿人。小修终于接受，前后经历3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Mon Mar 01 02:01:11 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210026, encodeId=49dc12100268b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝癌;临床 经验分享：去年12月投的，前后返修2次，审稿人问题很刁钻，昨天中的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c5dc5561694, createdName=苏苏sci, createdTime=Sun Apr 10 13:20:49 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240015, encodeId=62a212400155c, content=偏重的研究方向：手术;肝癌;临床 经验分享：临床文章。投稿后一个半月大修，基本没补什么东西，把图表和文本内容调整了一下，一个月后接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sat Aug 20 19:41:05 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=559626, encodeId=584555962608, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：不是很推荐，审稿慢，而且编辑意见很繁琐, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c00e1679674, createdName=landayb@163.com, createdTime=Fri Jul 27 21:36:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811857, encodeId=1f6281185ec1, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肝癌;放疗;手术 经验分享：刚投了一篇，一审大概一个月，5个审稿人，2个没提意见，2个人提了4-5条修改意见，1个主审稿人提了近20条意见。做的两种治疗比较的匹配分析。大修之后7月20日返回，8月20日刚收到接收的邮件。审稿人非常认真、仔细。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLEOiakaK8sYGAHicGEcRAQJm5kFbrR1MfFmlHuiaIb19JPJB28QibuEDJ5081W10d0NJiaL4Wf5mblq0Q/0, createdBy=03ec2202191, createdName=痞子孙小兵, createdTime=Fri Aug 21 17:00:50 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238700, encodeId=a0081238e00a3, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝脏 经验分享：记录一下helen小硕的第一篇SCI！投稿时间是2022年4月25日；最终接受的时间是2022年8月12日。首先杂志的审稿时间还是挺快的，有3个审稿人，送审之后不到3周就开始了第一次修回（大修）；修回之后之后仅有一个审稿人提出需要有一些基础的研究（小修），给了一个月的时间，补了一些基础实验，修回之后大概等了2-3周的时间，给出了最终接受的结果。杂志整体还是比较nice，希望每个科研人文章都可以顺利接受！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94b05588321, createdName=ms6000001864840275, createdTime=Sun Aug 14 23:17:23 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144690, encodeId=efb9214469024, content=2周了，状态还是正在提交给杂志，太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/adc0803ff06d9f6fc9d2bfc21391f246.jpg, createdBy=ac125183861, createdName=嘻嘻号, createdTime=Sun Jun 25 20:53:54 CST 2023, time=2023-06-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1212906, encodeId=5d6a121290653, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肝脏;肿瘤;临床 经验分享：年文章数：73，投稿相对难，每年发表数量太少，排的稿号数量又很大，很佛系的期刊，pubmed上看了近几年的文章，综述偏多，投的生信分析，等待时间约4周，编辑很委婉的建议投其他期刊，婉拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/24/c4699d591a16710e3be839693351aaf5.jpg, createdBy=41ed2099615, createdName=1821f639cdm, createdTime=Wed Apr 20 17:51:05 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061441, encodeId=e8b81061441d8, content=分数这么高的杂志为啥是中科院4区的呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/39439D60C1618DE672C0C92941D70C8F/100, createdBy=8eda2086410, createdName=ms7625496543595098, createdTime=Mon Oct 18 11:40:34 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956842, encodeId=27c795684297, content=去年12月投稿，4月接收，经历了大修，小修，总体感觉reviewer很认真，但比较好说话。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a0652638163, createdName=735766106, createdTime=Wed Apr 14 10:57:56 CST 2021, time=2021-04-14, status=1, ipAttribution=)]

2021-03-01 1dd96cb3m86(暂无匿称)

审稿速度:1.0 | 投稿命中率:25.0
经验分享：经过1个月大修，三个审稿人。小修终于接受，前后经历3个月。

136 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=944315, encodeId=e47f944315e8, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：经过1个月大修，三个审稿人。小修终于接受，前后经历3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Mon Mar 01 02:01:11 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210026, encodeId=49dc12100268b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝癌;临床 经验分享：去年12月投的，前后返修2次，审稿人问题很刁钻，昨天中的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c5dc5561694, createdName=苏苏sci, createdTime=Sun Apr 10 13:20:49 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240015, encodeId=62a212400155c, content=偏重的研究方向：手术;肝癌;临床 经验分享：临床文章。投稿后一个半月大修，基本没补什么东西，把图表和文本内容调整了一下，一个月后接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sat Aug 20 19:41:05 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=559626, encodeId=584555962608, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：不是很推荐，审稿慢，而且编辑意见很繁琐, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c00e1679674, createdName=landayb@163.com, createdTime=Fri Jul 27 21:36:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811857, encodeId=1f6281185ec1, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肝癌;放疗;手术 经验分享：刚投了一篇，一审大概一个月，5个审稿人，2个没提意见，2个人提了4-5条修改意见，1个主审稿人提了近20条意见。做的两种治疗比较的匹配分析。大修之后7月20日返回，8月20日刚收到接收的邮件。审稿人非常认真、仔细。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLEOiakaK8sYGAHicGEcRAQJm5kFbrR1MfFmlHuiaIb19JPJB28QibuEDJ5081W10d0NJiaL4Wf5mblq0Q/0, createdBy=03ec2202191, createdName=痞子孙小兵, createdTime=Fri Aug 21 17:00:50 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238700, encodeId=a0081238e00a3, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝脏 经验分享：记录一下helen小硕的第一篇SCI！投稿时间是2022年4月25日；最终接受的时间是2022年8月12日。首先杂志的审稿时间还是挺快的，有3个审稿人，送审之后不到3周就开始了第一次修回（大修）；修回之后之后仅有一个审稿人提出需要有一些基础的研究（小修），给了一个月的时间，补了一些基础实验，修回之后大概等了2-3周的时间，给出了最终接受的结果。杂志整体还是比较nice，希望每个科研人文章都可以顺利接受！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94b05588321, createdName=ms6000001864840275, createdTime=Sun Aug 14 23:17:23 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144690, encodeId=efb9214469024, content=2周了，状态还是正在提交给杂志，太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/adc0803ff06d9f6fc9d2bfc21391f246.jpg, createdBy=ac125183861, createdName=嘻嘻号, createdTime=Sun Jun 25 20:53:54 CST 2023, time=2023-06-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1212906, encodeId=5d6a121290653, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肝脏;肿瘤;临床 经验分享：年文章数：73，投稿相对难，每年发表数量太少，排的稿号数量又很大，很佛系的期刊，pubmed上看了近几年的文章，综述偏多，投的生信分析，等待时间约4周，编辑很委婉的建议投其他期刊，婉拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/24/c4699d591a16710e3be839693351aaf5.jpg, createdBy=41ed2099615, createdName=1821f639cdm, createdTime=Wed Apr 20 17:51:05 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061441, encodeId=e8b81061441d8, content=分数这么高的杂志为啥是中科院4区的呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/39439D60C1618DE672C0C92941D70C8F/100, createdBy=8eda2086410, createdName=ms7625496543595098, createdTime=Mon Oct 18 11:40:34 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956842, encodeId=27c795684297, content=去年12月投稿，4月接收，经历了大修，小修，总体感觉reviewer很认真，但比较好说话。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a0652638163, createdName=735766106, createdTime=Wed Apr 14 10:57:56 CST 2021, time=2021-04-14, status=1, ipAttribution=)]

2022-04-10 苏苏sci

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：肝癌;临床
经验分享：去年12月投的，前后返修2次，审稿人问题很刁钻，昨天中的

68 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=944315, encodeId=e47f944315e8, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：经过1个月大修，三个审稿人。小修终于接受，前后经历3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Mon Mar 01 02:01:11 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210026, encodeId=49dc12100268b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝癌;临床 经验分享：去年12月投的，前后返修2次，审稿人问题很刁钻，昨天中的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c5dc5561694, createdName=苏苏sci, createdTime=Sun Apr 10 13:20:49 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240015, encodeId=62a212400155c, content=偏重的研究方向：手术;肝癌;临床 经验分享：临床文章。投稿后一个半月大修，基本没补什么东西，把图表和文本内容调整了一下，一个月后接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sat Aug 20 19:41:05 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=559626, encodeId=584555962608, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：不是很推荐，审稿慢，而且编辑意见很繁琐, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c00e1679674, createdName=landayb@163.com, createdTime=Fri Jul 27 21:36:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811857, encodeId=1f6281185ec1, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肝癌;放疗;手术 经验分享：刚投了一篇，一审大概一个月，5个审稿人，2个没提意见，2个人提了4-5条修改意见，1个主审稿人提了近20条意见。做的两种治疗比较的匹配分析。大修之后7月20日返回，8月20日刚收到接收的邮件。审稿人非常认真、仔细。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLEOiakaK8sYGAHicGEcRAQJm5kFbrR1MfFmlHuiaIb19JPJB28QibuEDJ5081W10d0NJiaL4Wf5mblq0Q/0, createdBy=03ec2202191, createdName=痞子孙小兵, createdTime=Fri Aug 21 17:00:50 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238700, encodeId=a0081238e00a3, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝脏 经验分享：记录一下helen小硕的第一篇SCI！投稿时间是2022年4月25日；最终接受的时间是2022年8月12日。首先杂志的审稿时间还是挺快的，有3个审稿人，送审之后不到3周就开始了第一次修回（大修）；修回之后之后仅有一个审稿人提出需要有一些基础的研究（小修），给了一个月的时间，补了一些基础实验，修回之后大概等了2-3周的时间，给出了最终接受的结果。杂志整体还是比较nice，希望每个科研人文章都可以顺利接受！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94b05588321, createdName=ms6000001864840275, createdTime=Sun Aug 14 23:17:23 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144690, encodeId=efb9214469024, content=2周了，状态还是正在提交给杂志，太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/adc0803ff06d9f6fc9d2bfc21391f246.jpg, createdBy=ac125183861, createdName=嘻嘻号, createdTime=Sun Jun 25 20:53:54 CST 2023, time=2023-06-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1212906, encodeId=5d6a121290653, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肝脏;肿瘤;临床 经验分享：年文章数：73，投稿相对难，每年发表数量太少，排的稿号数量又很大，很佛系的期刊，pubmed上看了近几年的文章，综述偏多，投的生信分析，等待时间约4周，编辑很委婉的建议投其他期刊，婉拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/24/c4699d591a16710e3be839693351aaf5.jpg, createdBy=41ed2099615, createdName=1821f639cdm, createdTime=Wed Apr 20 17:51:05 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061441, encodeId=e8b81061441d8, content=分数这么高的杂志为啥是中科院4区的呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/39439D60C1618DE672C0C92941D70C8F/100, createdBy=8eda2086410, createdName=ms7625496543595098, createdTime=Mon Oct 18 11:40:34 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956842, encodeId=27c795684297, content=去年12月投稿，4月接收，经历了大修，小修，总体感觉reviewer很认真，但比较好说话。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a0652638163, createdName=735766106, createdTime=Wed Apr 14 10:57:56 CST 2021, time=2021-04-14, status=1, ipAttribution=)]

2022-08-20 YJJJJJ

偏重的研究方向：手术;肝癌;临床
经验分享：临床文章。投稿后一个半月大修，基本没补什么东西，把图表和文本内容调整了一下，一个月后接收。

43 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=944315, encodeId=e47f944315e8, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：经过1个月大修，三个审稿人。小修终于接受，前后经历3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Mon Mar 01 02:01:11 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210026, encodeId=49dc12100268b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝癌;临床 经验分享：去年12月投的，前后返修2次，审稿人问题很刁钻，昨天中的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c5dc5561694, createdName=苏苏sci, createdTime=Sun Apr 10 13:20:49 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240015, encodeId=62a212400155c, content=偏重的研究方向：手术;肝癌;临床 经验分享：临床文章。投稿后一个半月大修，基本没补什么东西，把图表和文本内容调整了一下，一个月后接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sat Aug 20 19:41:05 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=559626, encodeId=584555962608, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：不是很推荐，审稿慢，而且编辑意见很繁琐, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c00e1679674, createdName=landayb@163.com, createdTime=Fri Jul 27 21:36:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811857, encodeId=1f6281185ec1, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肝癌;放疗;手术 经验分享：刚投了一篇，一审大概一个月，5个审稿人，2个没提意见，2个人提了4-5条修改意见，1个主审稿人提了近20条意见。做的两种治疗比较的匹配分析。大修之后7月20日返回，8月20日刚收到接收的邮件。审稿人非常认真、仔细。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLEOiakaK8sYGAHicGEcRAQJm5kFbrR1MfFmlHuiaIb19JPJB28QibuEDJ5081W10d0NJiaL4Wf5mblq0Q/0, createdBy=03ec2202191, createdName=痞子孙小兵, createdTime=Fri Aug 21 17:00:50 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238700, encodeId=a0081238e00a3, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝脏 经验分享：记录一下helen小硕的第一篇SCI！投稿时间是2022年4月25日；最终接受的时间是2022年8月12日。首先杂志的审稿时间还是挺快的，有3个审稿人，送审之后不到3周就开始了第一次修回（大修）；修回之后之后仅有一个审稿人提出需要有一些基础的研究（小修），给了一个月的时间，补了一些基础实验，修回之后大概等了2-3周的时间，给出了最终接受的结果。杂志整体还是比较nice，希望每个科研人文章都可以顺利接受！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94b05588321, createdName=ms6000001864840275, createdTime=Sun Aug 14 23:17:23 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144690, encodeId=efb9214469024, content=2周了，状态还是正在提交给杂志，太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/adc0803ff06d9f6fc9d2bfc21391f246.jpg, createdBy=ac125183861, createdName=嘻嘻号, createdTime=Sun Jun 25 20:53:54 CST 2023, time=2023-06-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1212906, encodeId=5d6a121290653, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肝脏;肿瘤;临床 经验分享：年文章数：73，投稿相对难，每年发表数量太少，排的稿号数量又很大，很佛系的期刊，pubmed上看了近几年的文章，综述偏多，投的生信分析，等待时间约4周，编辑很委婉的建议投其他期刊，婉拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/24/c4699d591a16710e3be839693351aaf5.jpg, createdBy=41ed2099615, createdName=1821f639cdm, createdTime=Wed Apr 20 17:51:05 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061441, encodeId=e8b81061441d8, content=分数这么高的杂志为啥是中科院4区的呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/39439D60C1618DE672C0C92941D70C8F/100, createdBy=8eda2086410, createdName=ms7625496543595098, createdTime=Mon Oct 18 11:40:34 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956842, encodeId=27c795684297, content=去年12月投稿，4月接收，经历了大修，小修，总体感觉reviewer很认真，但比较好说话。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a0652638163, createdName=735766106, createdTime=Wed Apr 14 10:57:56 CST 2021, time=2021-04-14, status=1, ipAttribution=)]

2018-07-27 landayb@163.com

审稿速度:3.0 | 投稿命中率:25.0
经验分享：不是很推荐，审稿慢，而且编辑意见很繁琐

110 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=944315, encodeId=e47f944315e8, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：经过1个月大修，三个审稿人。小修终于接受，前后经历3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Mon Mar 01 02:01:11 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210026, encodeId=49dc12100268b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝癌;临床 经验分享：去年12月投的，前后返修2次，审稿人问题很刁钻，昨天中的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c5dc5561694, createdName=苏苏sci, createdTime=Sun Apr 10 13:20:49 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240015, encodeId=62a212400155c, content=偏重的研究方向：手术;肝癌;临床 经验分享：临床文章。投稿后一个半月大修，基本没补什么东西，把图表和文本内容调整了一下，一个月后接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sat Aug 20 19:41:05 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=559626, encodeId=584555962608, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：不是很推荐，审稿慢，而且编辑意见很繁琐, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c00e1679674, createdName=landayb@163.com, createdTime=Fri Jul 27 21:36:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811857, encodeId=1f6281185ec1, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肝癌;放疗;手术 经验分享：刚投了一篇，一审大概一个月，5个审稿人，2个没提意见，2个人提了4-5条修改意见，1个主审稿人提了近20条意见。做的两种治疗比较的匹配分析。大修之后7月20日返回，8月20日刚收到接收的邮件。审稿人非常认真、仔细。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLEOiakaK8sYGAHicGEcRAQJm5kFbrR1MfFmlHuiaIb19JPJB28QibuEDJ5081W10d0NJiaL4Wf5mblq0Q/0, createdBy=03ec2202191, createdName=痞子孙小兵, createdTime=Fri Aug 21 17:00:50 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238700, encodeId=a0081238e00a3, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝脏 经验分享：记录一下helen小硕的第一篇SCI！投稿时间是2022年4月25日；最终接受的时间是2022年8月12日。首先杂志的审稿时间还是挺快的，有3个审稿人，送审之后不到3周就开始了第一次修回（大修）；修回之后之后仅有一个审稿人提出需要有一些基础的研究（小修），给了一个月的时间，补了一些基础实验，修回之后大概等了2-3周的时间，给出了最终接受的结果。杂志整体还是比较nice，希望每个科研人文章都可以顺利接受！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94b05588321, createdName=ms6000001864840275, createdTime=Sun Aug 14 23:17:23 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144690, encodeId=efb9214469024, content=2周了，状态还是正在提交给杂志，太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/adc0803ff06d9f6fc9d2bfc21391f246.jpg, createdBy=ac125183861, createdName=嘻嘻号, createdTime=Sun Jun 25 20:53:54 CST 2023, time=2023-06-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1212906, encodeId=5d6a121290653, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肝脏;肿瘤;临床 经验分享：年文章数：73，投稿相对难，每年发表数量太少，排的稿号数量又很大，很佛系的期刊，pubmed上看了近几年的文章，综述偏多，投的生信分析，等待时间约4周，编辑很委婉的建议投其他期刊，婉拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/24/c4699d591a16710e3be839693351aaf5.jpg, createdBy=41ed2099615, createdName=1821f639cdm, createdTime=Wed Apr 20 17:51:05 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061441, encodeId=e8b81061441d8, content=分数这么高的杂志为啥是中科院4区的呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/39439D60C1618DE672C0C92941D70C8F/100, createdBy=8eda2086410, createdName=ms7625496543595098, createdTime=Mon Oct 18 11:40:34 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956842, encodeId=27c795684297, content=去年12月投稿，4月接收，经历了大修，小修，总体感觉reviewer很认真，但比较好说话。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a0652638163, createdName=735766106, createdTime=Wed Apr 14 10:57:56 CST 2021, time=2021-04-14, status=1, ipAttribution=)]

2020-08-21 痞子孙小兵

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：肝癌;放疗;手术
经验分享：刚投了一篇，一审大概一个月，5个审稿人，2个没提意见，2个人提了4-5条修改意见，1个主审稿人提了近20条意见。做的两种治疗比较的匹配分析。大修之后7月20日返回，8月20日刚收到接收的邮件。审稿人非常认真、仔细。

133 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=944315, encodeId=e47f944315e8, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：经过1个月大修，三个审稿人。小修终于接受，前后经历3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Mon Mar 01 02:01:11 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210026, encodeId=49dc12100268b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝癌;临床 经验分享：去年12月投的，前后返修2次，审稿人问题很刁钻，昨天中的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c5dc5561694, createdName=苏苏sci, createdTime=Sun Apr 10 13:20:49 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240015, encodeId=62a212400155c, content=偏重的研究方向：手术;肝癌;临床 经验分享：临床文章。投稿后一个半月大修，基本没补什么东西，把图表和文本内容调整了一下，一个月后接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sat Aug 20 19:41:05 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=559626, encodeId=584555962608, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：不是很推荐，审稿慢，而且编辑意见很繁琐, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c00e1679674, createdName=landayb@163.com, createdTime=Fri Jul 27 21:36:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811857, encodeId=1f6281185ec1, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肝癌;放疗;手术 经验分享：刚投了一篇，一审大概一个月，5个审稿人，2个没提意见，2个人提了4-5条修改意见，1个主审稿人提了近20条意见。做的两种治疗比较的匹配分析。大修之后7月20日返回，8月20日刚收到接收的邮件。审稿人非常认真、仔细。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLEOiakaK8sYGAHicGEcRAQJm5kFbrR1MfFmlHuiaIb19JPJB28QibuEDJ5081W10d0NJiaL4Wf5mblq0Q/0, createdBy=03ec2202191, createdName=痞子孙小兵, createdTime=Fri Aug 21 17:00:50 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238700, encodeId=a0081238e00a3, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝脏 经验分享：记录一下helen小硕的第一篇SCI！投稿时间是2022年4月25日；最终接受的时间是2022年8月12日。首先杂志的审稿时间还是挺快的，有3个审稿人，送审之后不到3周就开始了第一次修回（大修）；修回之后之后仅有一个审稿人提出需要有一些基础的研究（小修），给了一个月的时间，补了一些基础实验，修回之后大概等了2-3周的时间，给出了最终接受的结果。杂志整体还是比较nice，希望每个科研人文章都可以顺利接受！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94b05588321, createdName=ms6000001864840275, createdTime=Sun Aug 14 23:17:23 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144690, encodeId=efb9214469024, content=2周了，状态还是正在提交给杂志，太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/adc0803ff06d9f6fc9d2bfc21391f246.jpg, createdBy=ac125183861, createdName=嘻嘻号, createdTime=Sun Jun 25 20:53:54 CST 2023, time=2023-06-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1212906, encodeId=5d6a121290653, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肝脏;肿瘤;临床 经验分享：年文章数：73，投稿相对难，每年发表数量太少，排的稿号数量又很大，很佛系的期刊，pubmed上看了近几年的文章，综述偏多，投的生信分析，等待时间约4周，编辑很委婉的建议投其他期刊，婉拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/24/c4699d591a16710e3be839693351aaf5.jpg, createdBy=41ed2099615, createdName=1821f639cdm, createdTime=Wed Apr 20 17:51:05 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061441, encodeId=e8b81061441d8, content=分数这么高的杂志为啥是中科院4区的呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/39439D60C1618DE672C0C92941D70C8F/100, createdBy=8eda2086410, createdName=ms7625496543595098, createdTime=Mon Oct 18 11:40:34 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956842, encodeId=27c795684297, content=去年12月投稿，4月接收，经历了大修，小修，总体感觉reviewer很认真，但比较好说话。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a0652638163, createdName=735766106, createdTime=Wed Apr 14 10:57:56 CST 2021, time=2021-04-14, status=1, ipAttribution=)]

2022-08-14 ms6000001864840275

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：肝脏
经验分享：记录一下helen小硕的第一篇SCI！投稿时间是2022年4月25日；最终接受的时间是2022年8月12日。首先杂志的审稿时间还是挺快的，有3个审稿人，送审之后不到3周就开始了第一次修回（大修）；修回之后之后仅有一个审稿人提出需要有一些基础的研究（小修），给了一个月的时间，补了一些基础实验，修回之后大概等了2-3周的时间，给出了最终接受的结果。杂志整体还是比较nice，希望每个科研人文章都可以顺利接受！

62 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=944315, encodeId=e47f944315e8, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：经过1个月大修，三个审稿人。小修终于接受，前后经历3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Mon Mar 01 02:01:11 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210026, encodeId=49dc12100268b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝癌;临床 经验分享：去年12月投的，前后返修2次，审稿人问题很刁钻，昨天中的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c5dc5561694, createdName=苏苏sci, createdTime=Sun Apr 10 13:20:49 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240015, encodeId=62a212400155c, content=偏重的研究方向：手术;肝癌;临床 经验分享：临床文章。投稿后一个半月大修，基本没补什么东西，把图表和文本内容调整了一下，一个月后接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sat Aug 20 19:41:05 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=559626, encodeId=584555962608, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：不是很推荐，审稿慢，而且编辑意见很繁琐, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c00e1679674, createdName=landayb@163.com, createdTime=Fri Jul 27 21:36:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811857, encodeId=1f6281185ec1, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肝癌;放疗;手术 经验分享：刚投了一篇，一审大概一个月，5个审稿人，2个没提意见，2个人提了4-5条修改意见，1个主审稿人提了近20条意见。做的两种治疗比较的匹配分析。大修之后7月20日返回，8月20日刚收到接收的邮件。审稿人非常认真、仔细。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLEOiakaK8sYGAHicGEcRAQJm5kFbrR1MfFmlHuiaIb19JPJB28QibuEDJ5081W10d0NJiaL4Wf5mblq0Q/0, createdBy=03ec2202191, createdName=痞子孙小兵, createdTime=Fri Aug 21 17:00:50 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238700, encodeId=a0081238e00a3, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝脏 经验分享：记录一下helen小硕的第一篇SCI！投稿时间是2022年4月25日；最终接受的时间是2022年8月12日。首先杂志的审稿时间还是挺快的，有3个审稿人，送审之后不到3周就开始了第一次修回（大修）；修回之后之后仅有一个审稿人提出需要有一些基础的研究（小修），给了一个月的时间，补了一些基础实验，修回之后大概等了2-3周的时间，给出了最终接受的结果。杂志整体还是比较nice，希望每个科研人文章都可以顺利接受！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94b05588321, createdName=ms6000001864840275, createdTime=Sun Aug 14 23:17:23 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144690, encodeId=efb9214469024, content=2周了，状态还是正在提交给杂志，太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/adc0803ff06d9f6fc9d2bfc21391f246.jpg, createdBy=ac125183861, createdName=嘻嘻号, createdTime=Sun Jun 25 20:53:54 CST 2023, time=2023-06-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1212906, encodeId=5d6a121290653, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肝脏;肿瘤;临床 经验分享：年文章数：73，投稿相对难，每年发表数量太少，排的稿号数量又很大，很佛系的期刊，pubmed上看了近几年的文章，综述偏多，投的生信分析，等待时间约4周，编辑很委婉的建议投其他期刊，婉拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/24/c4699d591a16710e3be839693351aaf5.jpg, createdBy=41ed2099615, createdName=1821f639cdm, createdTime=Wed Apr 20 17:51:05 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061441, encodeId=e8b81061441d8, content=分数这么高的杂志为啥是中科院4区的呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/39439D60C1618DE672C0C92941D70C8F/100, createdBy=8eda2086410, createdName=ms7625496543595098, createdTime=Mon Oct 18 11:40:34 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956842, encodeId=27c795684297, content=去年12月投稿，4月接收，经历了大修，小修，总体感觉reviewer很认真，但比较好说话。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a0652638163, createdName=735766106, createdTime=Wed Apr 14 10:57:56 CST 2021, time=2021-04-14, status=1, ipAttribution=)]

2023-06-25 嘻嘻号来自江苏省

2周了，状态还是正在提交给杂志，太慢了

39 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=944315, encodeId=e47f944315e8, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：经过1个月大修，三个审稿人。小修终于接受，前后经历3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Mon Mar 01 02:01:11 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210026, encodeId=49dc12100268b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝癌;临床 经验分享：去年12月投的，前后返修2次，审稿人问题很刁钻，昨天中的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c5dc5561694, createdName=苏苏sci, createdTime=Sun Apr 10 13:20:49 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240015, encodeId=62a212400155c, content=偏重的研究方向：手术;肝癌;临床 经验分享：临床文章。投稿后一个半月大修，基本没补什么东西，把图表和文本内容调整了一下，一个月后接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sat Aug 20 19:41:05 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=559626, encodeId=584555962608, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：不是很推荐，审稿慢，而且编辑意见很繁琐, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c00e1679674, createdName=landayb@163.com, createdTime=Fri Jul 27 21:36:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811857, encodeId=1f6281185ec1, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肝癌;放疗;手术 经验分享：刚投了一篇，一审大概一个月，5个审稿人，2个没提意见，2个人提了4-5条修改意见，1个主审稿人提了近20条意见。做的两种治疗比较的匹配分析。大修之后7月20日返回，8月20日刚收到接收的邮件。审稿人非常认真、仔细。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLEOiakaK8sYGAHicGEcRAQJm5kFbrR1MfFmlHuiaIb19JPJB28QibuEDJ5081W10d0NJiaL4Wf5mblq0Q/0, createdBy=03ec2202191, createdName=痞子孙小兵, createdTime=Fri Aug 21 17:00:50 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238700, encodeId=a0081238e00a3, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝脏 经验分享：记录一下helen小硕的第一篇SCI！投稿时间是2022年4月25日；最终接受的时间是2022年8月12日。首先杂志的审稿时间还是挺快的，有3个审稿人，送审之后不到3周就开始了第一次修回（大修）；修回之后之后仅有一个审稿人提出需要有一些基础的研究（小修），给了一个月的时间，补了一些基础实验，修回之后大概等了2-3周的时间，给出了最终接受的结果。杂志整体还是比较nice，希望每个科研人文章都可以顺利接受！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94b05588321, createdName=ms6000001864840275, createdTime=Sun Aug 14 23:17:23 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144690, encodeId=efb9214469024, content=2周了，状态还是正在提交给杂志，太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/adc0803ff06d9f6fc9d2bfc21391f246.jpg, createdBy=ac125183861, createdName=嘻嘻号, createdTime=Sun Jun 25 20:53:54 CST 2023, time=2023-06-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1212906, encodeId=5d6a121290653, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肝脏;肿瘤;临床 经验分享：年文章数：73，投稿相对难，每年发表数量太少，排的稿号数量又很大，很佛系的期刊，pubmed上看了近几年的文章，综述偏多，投的生信分析，等待时间约4周，编辑很委婉的建议投其他期刊，婉拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/24/c4699d591a16710e3be839693351aaf5.jpg, createdBy=41ed2099615, createdName=1821f639cdm, createdTime=Wed Apr 20 17:51:05 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061441, encodeId=e8b81061441d8, content=分数这么高的杂志为啥是中科院4区的呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/39439D60C1618DE672C0C92941D70C8F/100, createdBy=8eda2086410, createdName=ms7625496543595098, createdTime=Mon Oct 18 11:40:34 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956842, encodeId=27c795684297, content=去年12月投稿，4月接收，经历了大修，小修，总体感觉reviewer很认真，但比较好说话。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a0652638163, createdName=735766106, createdTime=Wed Apr 14 10:57:56 CST 2021, time=2021-04-14, status=1, ipAttribution=)]

2022-04-20 1821f639cdm

审稿速度:3.0 | 投稿命中率:5.0
偏重的研究方向：肝脏;肿瘤;临床
经验分享：年文章数：73，投稿相对难，每年发表数量太少，排的稿号数量又很大，很佛系的期刊，pubmed上看了近几年的文章，综述偏多，投的生信分析，等待时间约4周，编辑很委婉的建议投其他期刊，婉拒

70 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=944315, encodeId=e47f944315e8, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：经过1个月大修，三个审稿人。小修终于接受，前后经历3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Mon Mar 01 02:01:11 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210026, encodeId=49dc12100268b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝癌;临床 经验分享：去年12月投的，前后返修2次，审稿人问题很刁钻，昨天中的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c5dc5561694, createdName=苏苏sci, createdTime=Sun Apr 10 13:20:49 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240015, encodeId=62a212400155c, content=偏重的研究方向：手术;肝癌;临床 经验分享：临床文章。投稿后一个半月大修，基本没补什么东西，把图表和文本内容调整了一下，一个月后接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sat Aug 20 19:41:05 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=559626, encodeId=584555962608, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：不是很推荐，审稿慢，而且编辑意见很繁琐, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c00e1679674, createdName=landayb@163.com, createdTime=Fri Jul 27 21:36:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811857, encodeId=1f6281185ec1, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肝癌;放疗;手术 经验分享：刚投了一篇，一审大概一个月，5个审稿人，2个没提意见，2个人提了4-5条修改意见，1个主审稿人提了近20条意见。做的两种治疗比较的匹配分析。大修之后7月20日返回，8月20日刚收到接收的邮件。审稿人非常认真、仔细。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLEOiakaK8sYGAHicGEcRAQJm5kFbrR1MfFmlHuiaIb19JPJB28QibuEDJ5081W10d0NJiaL4Wf5mblq0Q/0, createdBy=03ec2202191, createdName=痞子孙小兵, createdTime=Fri Aug 21 17:00:50 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238700, encodeId=a0081238e00a3, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝脏 经验分享：记录一下helen小硕的第一篇SCI！投稿时间是2022年4月25日；最终接受的时间是2022年8月12日。首先杂志的审稿时间还是挺快的，有3个审稿人，送审之后不到3周就开始了第一次修回（大修）；修回之后之后仅有一个审稿人提出需要有一些基础的研究（小修），给了一个月的时间，补了一些基础实验，修回之后大概等了2-3周的时间，给出了最终接受的结果。杂志整体还是比较nice，希望每个科研人文章都可以顺利接受！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94b05588321, createdName=ms6000001864840275, createdTime=Sun Aug 14 23:17:23 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144690, encodeId=efb9214469024, content=2周了，状态还是正在提交给杂志，太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/adc0803ff06d9f6fc9d2bfc21391f246.jpg, createdBy=ac125183861, createdName=嘻嘻号, createdTime=Sun Jun 25 20:53:54 CST 2023, time=2023-06-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1212906, encodeId=5d6a121290653, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肝脏;肿瘤;临床 经验分享：年文章数：73，投稿相对难，每年发表数量太少，排的稿号数量又很大，很佛系的期刊，pubmed上看了近几年的文章，综述偏多，投的生信分析，等待时间约4周，编辑很委婉的建议投其他期刊，婉拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/24/c4699d591a16710e3be839693351aaf5.jpg, createdBy=41ed2099615, createdName=1821f639cdm, createdTime=Wed Apr 20 17:51:05 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061441, encodeId=e8b81061441d8, content=分数这么高的杂志为啥是中科院4区的呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/39439D60C1618DE672C0C92941D70C8F/100, createdBy=8eda2086410, createdName=ms7625496543595098, createdTime=Mon Oct 18 11:40:34 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956842, encodeId=27c795684297, content=去年12月投稿，4月接收，经历了大修，小修，总体感觉reviewer很认真，但比较好说话。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a0652638163, createdName=735766106, createdTime=Wed Apr 14 10:57:56 CST 2021, time=2021-04-14, status=1, ipAttribution=)]

2021-10-18 ms7625496543595098

分数这么高的杂志为啥是中科院4区的呢

73 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=944315, encodeId=e47f944315e8, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：经过1个月大修，三个审稿人。小修终于接受，前后经历3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Mon Mar 01 02:01:11 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210026, encodeId=49dc12100268b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝癌;临床 经验分享：去年12月投的，前后返修2次，审稿人问题很刁钻，昨天中的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c5dc5561694, createdName=苏苏sci, createdTime=Sun Apr 10 13:20:49 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240015, encodeId=62a212400155c, content=偏重的研究方向：手术;肝癌;临床 经验分享：临床文章。投稿后一个半月大修，基本没补什么东西，把图表和文本内容调整了一下，一个月后接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sat Aug 20 19:41:05 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=559626, encodeId=584555962608, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：不是很推荐，审稿慢，而且编辑意见很繁琐, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c00e1679674, createdName=landayb@163.com, createdTime=Fri Jul 27 21:36:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811857, encodeId=1f6281185ec1, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肝癌;放疗;手术 经验分享：刚投了一篇，一审大概一个月，5个审稿人，2个没提意见，2个人提了4-5条修改意见，1个主审稿人提了近20条意见。做的两种治疗比较的匹配分析。大修之后7月20日返回，8月20日刚收到接收的邮件。审稿人非常认真、仔细。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLEOiakaK8sYGAHicGEcRAQJm5kFbrR1MfFmlHuiaIb19JPJB28QibuEDJ5081W10d0NJiaL4Wf5mblq0Q/0, createdBy=03ec2202191, createdName=痞子孙小兵, createdTime=Fri Aug 21 17:00:50 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238700, encodeId=a0081238e00a3, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝脏 经验分享：记录一下helen小硕的第一篇SCI！投稿时间是2022年4月25日；最终接受的时间是2022年8月12日。首先杂志的审稿时间还是挺快的，有3个审稿人，送审之后不到3周就开始了第一次修回（大修）；修回之后之后仅有一个审稿人提出需要有一些基础的研究（小修），给了一个月的时间，补了一些基础实验，修回之后大概等了2-3周的时间，给出了最终接受的结果。杂志整体还是比较nice，希望每个科研人文章都可以顺利接受！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94b05588321, createdName=ms6000001864840275, createdTime=Sun Aug 14 23:17:23 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144690, encodeId=efb9214469024, content=2周了，状态还是正在提交给杂志，太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/adc0803ff06d9f6fc9d2bfc21391f246.jpg, createdBy=ac125183861, createdName=嘻嘻号, createdTime=Sun Jun 25 20:53:54 CST 2023, time=2023-06-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1212906, encodeId=5d6a121290653, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肝脏;肿瘤;临床 经验分享：年文章数：73，投稿相对难，每年发表数量太少，排的稿号数量又很大，很佛系的期刊，pubmed上看了近几年的文章，综述偏多，投的生信分析，等待时间约4周，编辑很委婉的建议投其他期刊，婉拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/24/c4699d591a16710e3be839693351aaf5.jpg, createdBy=41ed2099615, createdName=1821f639cdm, createdTime=Wed Apr 20 17:51:05 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061441, encodeId=e8b81061441d8, content=分数这么高的杂志为啥是中科院4区的呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/39439D60C1618DE672C0C92941D70C8F/100, createdBy=8eda2086410, createdName=ms7625496543595098, createdTime=Mon Oct 18 11:40:34 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956842, encodeId=27c795684297, content=去年12月投稿，4月接收，经历了大修，小修，总体感觉reviewer很认真，但比较好说话。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a0652638163, createdName=735766106, createdTime=Wed Apr 14 10:57:56 CST 2021, time=2021-04-14, status=1, ipAttribution=)]

2021-04-14 735766106

去年12月投稿，4月接收，经历了大修，小修，总体感觉reviewer很认真，但比较好说话。

92 2

展开2条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务